Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of action

Allan Saul, Heidi E. Drummer, Nick Scott, Tim Spelman, Brendan S. Crabb, Margaret Hellard
doi: https://doi.org/10.1101/2021.02.23.21252315

Article usage

Article usage: March 2021 to November 2024

AbstractFullPdf
Mar 20212216615567
Apr 202170678191
May 20215076799
Jun 20214682271
Jul 20212951152
Aug 20212401251
Sep 20211951549
Oct 20212691954
Nov 2021148444
Dec 2021106756
Jan 20221301018
Feb 202274232
Mar 202255122
Apr 2022641027
May 202241423
Jun 202258180
Jul 202246371
Aug 202235118
Sep 202252221
Oct 202249315
Nov 202234110
Dec 202267614
Jan 2023144515
Feb 202312169
Mar 20239414
Apr 2023621418
May 2023822026
Jun 202322114
Jul 202314212
Aug 202333109
Sep 20233558
Oct 202324211
Nov 20232207
Dec 202321210
Jan 202413046
Feb 202422414
Mar 202417415
Apr 202430515
May 202431312
Jun 20243697
Jul 202431110
Aug 202442514
Sep 20241538
Oct 20241075
Nov 202416313
Back to top
Posted March 01, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of action
Allan Saul, Heidi E. Drummer, Nick Scott, Tim Spelman, Brendan S. Crabb, Margaret Hellard
medRxiv 2021.02.23.21252315; doi: https://doi.org/10.1101/2021.02.23.21252315
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area